Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved DigiFab™. DigiFab™ is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose.
"DigiFab™ provides an important opportunity to grow Paladin's specialty and orphan franchise which includes Replagal®, Elaprase® and Antizol®," said Jonathan Ross Goodman, President and Chief Executive Officer of Paladin Labs Inc. "Following approval, DigiFab™ will provide patients and physicians with a new option for the treatment digoxin poisoning."Get decorating inspiration from Shelter pop.com. Articles and videos walk you through subjects like window treatments, flooring, and giving a room a cool industrial look. For more crafty ideas, like a DIY wine rack, download free "Decor It Yourself" video podcasts on iTunes.Turn any picture into a megasize poster. The Rasterbator (the-rasterbator .en.softonic.com) blows up any uploaded image into a large raster graphic (that is, a bunch of pixels). It spreads those pixels across several pages-or several hundred-in a PDF that you can download, print, and assemble on your wall.Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. For more information, please visit the Company's web site at www.paladinlabs.com5 DESIGNER IMPOSTERSAbout Paladin Labs
Contacts: Paladin Labs Inc. Samira Sakhia, Chief Financial Officer 514-669-5367 514-344-4675 (FAX) info@paladinlabs.com www.paladinlabs.com
No comments:
Post a Comment